Bronchitis Treatment Market By Type Of Drug Class (Antitussives/ Expectorants, Bronchodilators, Beta-Adrenergic Agonist, Systemic Corticosteroids, Inhaled Corticosteroids, Phosphodiesterase-4 Inhibitors, Analgesics, Antibiotics) - Growth, Future Prospects, Competitive Analysis, 2018 - 2026

Industry Outlook

The bronchitis treatment market had a market value of US$ 3,345.8 million in 2017 and is expected to grow at a CAGR of 4.9% between 2018 and 2026. The bronchitis treatment market is growing gradually throughout the forecast period due to a strong product pipeline equipped with target-specific drugs and rising prevalence and awareness related to the treatment and diagnosis of bronchitis. The major cause of bronchitis is frequent cigarette smoking, coupled with exposure to air pollutants. As a result, the overall growth of global bronchitis treatment is significant and is expected to continue throughout the forecast year, thanks to upcoming drugs currently undergoing trials.

Market Synopsis

Continuous research and development in the field of bronchitis treatment are expected to bring novel drugs to the market and ultimately assist the overall growth of the industry.

During the forecast period from 2018 to 2026, phosphodiesterase-4 inhibitors were identified as the fastest-growing segment due to major factors such as the fact that Roflumilast is beneficial in chronic bronchitis to decrease exacerbations and relieve dyspnea, and physicians treat chronic bronchitis on a priority basis as it is more complex compared to acute bronchitis. Roflumilast also plays a key role in improving lung function and assisting the recovery of patients. Thus, novel drugs entering the market will increase the growth of the overall bronchitis treatment market, as there is huge market demand for target-specific drugs.

Increasing prevalence and awareness related to bronchitis in Asia-Pacific make it the fastest-growing region throughout the forecast period.

The Asia Pacific will grow significantly throughout the forecast period from 2018 to 2026. The key factors responsible for the growth of the bronchitis treatment market in this region are the rising prevalence of bronchitis due to high levels of air pollution and smoking and increasing awareness and accessibility related to bronchitis treatment. There are several awareness campaigns carried out by the government and non-government organizations in developing countries in the Asia Pacific, such as China, India, Indonesia, and Thailand, due to which the bronchitis treatment market is growing significantly in this region. China and India have the highest rates of bronchitis, which is primarily due to air pollution and their large cigarette-smoking populations. According to the World Health Organization (WHO), it has been recorded that in Asia, around one-third, or 2.2 million, of the world’s 7 million premature deaths occur due to respiratory disorders caused by air pollution each year.

Periods of History and Forecast

The bronchitis treatment market was analyzed considering current market trends for the base year of 2017, and based on future trends, CAGRs were calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report provides an in-depth analysis related to the bronchitis treatment market, covering market elucidations and assumptions based on in-depth qualitative and quantitative data collected through primary and secondary research. Stakeholders in the industry have helped analyze and study market dynamics such as drivers, opportunities, and challenges, which have been further concentrated at the regional and country levels. This report also includes a comprehensive analysis of the global bronchitis treatment market, segmented by type of drug and geography. The report also gives information related to the competitive landscape of the major players present and operating in the bronchitis treatment market that covers in-depth company information such as the latest business strategies, financial data, and product profiles.

The key manufacturers present in the market were reported based on their product portfolios, current market updates, financial information, and key strategies. This report also includes attractive investment propositions studied with the aid of PESTEL analysis, which is based on detailed geographical research. Major companies studied in the overall report are AstraZeneca Plc, DVB Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucositis BV, among others.

Key questions are answered in this report.

  • Which is the trending drug class type in the market preferred for bronchitis treatment, and why?
  • What are the current market strategies and policies that key companies are planning and implementing, as well as the competitive landscape of the bronchitis treatment market?
  • Which are the important and potential geographical markets (regions and countries) in the bronchitis treatment market?
  • Which is the largest and fastest-growing region globally?

Frequently Asked Questions:

The market for Bronchitis Treatment Market is expected to reach At US$ 3,345.8 Mn in 2026.

The Bronchitis Treatment Market is expected to see significant CAGR growth over the coming years, at 4.9%.

The report is forecasted to 2018-2026

The base year of this report is 2017.

Advanced Inhalation Therapies (AIT) Ltd., Financial Information (Subject to data availability),Product Portfolio,F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Mar 2019
Category:  Pharmaceuticals
Report ID:   59646
Report Format:   PDF
Pages:   120
Rating:    4.2 (49)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support